| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EBITDA | -24,6 k € | -24.9% | -19,7 k € | -166.8% | 29,5 k € | -89.2% | 272,2 k € | -93.9% | 4,5 M € | +17505.8% | -25,6 k € | -100.5% | 5,4 M € | +458.7% | -1,5 M € | +95.8% | -35,9 M € | -295.7% | 18,3 M € | +177.0% | -23,8 M € | -129.3% | -10,4 M € | -112.6% | 82,2 M € | +343.3% | -33,8 M € | +51.1% | -69,1 M € | -20.5% | -57,4 M € | |
| Operating profit | -24,6 k € | -24.9% | -19,7 k € | -166.8% | 29,5 k € | -89.2% | 272,2 k € | -93.9% | 4,5 M € | +17505.8% | -25,6 k € | -100.5% | 5,4 M € | +458.7% | -1,5 M € | +95.8% | -35,9 M € | -295.7% | 18,3 M € | +177.0% | -23,8 M € | -129.3% | -10,4 M € | -112.6% | 82,2 M € | +343.3% | -33,8 M € | +51.1% | -69,1 M € | -20.5% | -57,4 M € | |
| Profit/loss | 905,0 k € | -59.8% | 2,2 M € | +237.2% | 667,1 k € | -19.9% | 832,6 k € | -81.8% | 4,6 M € | +13167.0% | -35,0 k € | -100.6% | 6,2 M € | +1741.9% | 338,2 k € | +100.9% | -35,8 M € | -295.3% | 18,3 M € | +160.0% | -30,6 M € | -545.6% | 6,9 M € | -96.6% | 203,0 M € | -3.2% | 209,8 M € | +346.1% | -85,3 M € | +86.0% | -607,0 M € | |
| Equity | 133,3 k € | -41.6% | 228,3 k € | +27.5% | 179,1 k € | -15.5% | 212,0 k € | -75.9% | 879,4 k € | -86.1% | 6,3 M € | -0.6% | 6,3 M € | -88.1% | 53,1 M € | +0.6% | 52,7 M € | -40.5% | 88,6 M € | +26.1% | 70,2 M € | -76.8% | 302,5 M € | -82.5% | 1,7 Md € | +13.3% | 1,5 Md € | -35.3% | 2,4 Md € | -3.5% | 2,4 Md € | |
| Total assets | 28,1 M € | -14.5% | 32,8 M € | +11.9% | 29,3 M € | -6.4% | 31,4 M € | -19.7% | 39,1 M € | +3.9% | 37,6 M € | -6.1% | 40,1 M € | -59.8% | 99,6 M € | +2.1% | 97,6 M € | -3.3% | 100,9 M € | -1.4% | 102,3 M € | -71.4% | 357,9 M € | -79.7% | 1,8 Md € | +9.4% | 1,6 Md € | -34.8% | 2,5 Md € | +0.3% | 2,5 Md € | |
| Cash | — | — | 28,5 € | — | — | — | 1,0 € | — | — | — | 256,1 € | +6.1% | 241,3 € | +7.0% | 225,5 € | -5.6% | 238,7 € | -74.8% | 946,0 € | -0.0% | 946,4 € | |||||||||||
| Debts | 1,5 M € | -44.7% | 2,7 M € | +160.6% | 1,0 M € | -48.9% | 2,0 M € | -81.2% | 10,7 M € | +1448.8% | 692,6 k € | -0.9% | 699,1 k € | -14.5% | 817,5 k € | -16.7% | 981,3 k € | -49.2% | 1,9 M € | +22.7% | 1,6 M € | -95.1% | 32,3 M € | +550.3% | 5,0 M € | +125.1% | 2,2 M € | -95.6% | 50,1 M € | +341.6% | 11,4 M € | |
| Staff | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 1 | 2,8 | ||||||||||||||||
Public limited company · Bruxelles · incorporated on 28/11/2005
Public limited company profitable but thinly capitalised. Cash position rising (+2842.3%).
Solid counterparty for a standard engagement.
SOLVAY PHARMACEUTICALS SA is a Public limited company incorporated in 2005. Its main activity is: Activities of head offices. Its registered office is in Bruxelles.
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette